Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03849651 · OUTCOME

The Cumulative Incidence of Transplant Related Mortality

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies · Source last updated 2026-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
100 days after receiving transplant

What was measured

Kalbfleisch and Prentice estimate of the percentage of experiencing TRM 100 days after the date of transplant. (Events=TRM, competing events=relapse)

Analysis population: Patients who met eligibility criteria and received transplant.

Groups in this outcome

All Transplant Participants

Patients who met eligibility criteria and received transplant.

Dose 1

Patients who met eligibility criteria, received transplant, and received 1x10\^5 cells/kg

Dose 2

Patients who met eligibility criteria, received transplant, and received 1x10\^6 cells/kg

Dose 3

Patients who met eligibility criteria, received transplant, and received 1x10\^7 cells/kg

Phase 2

Patients who met eligibility criteria, received transplant, and were assigned the MED dose of 1x10\^7 cells/kg

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Transplant Participants69
Dose 19
Dose 210
Dose 310
Phase 240

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Transplant Participants0Not reportedNot reportedNot reportedNot reported
Dose 10Not reportedNot reportedNot reportedNot reported
Dose 20Not reportedNot reportedNot reportedNot reported
Dose 30Not reportedNot reportedNot reportedNot reported
Phase 20Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      69
    2. group Id
      OG001
      value
      9
    3. group Id
      OG002
      value
      10
    4. group Id
      OG003
      value
      10
    5. group Id
      OG004
      value
      40
    units
    Participants
description
Kalbfleisch and Prentice estimate of the percentage of experiencing TRM 100 days after the date of transplant. (Events=TRM, competing events=relapse)
groups
  1. description
    Patients who met eligibility criteria and received transplant.
    id
    OG000
    title
    All Transplant Participants
  2. description
    Patients who met eligibility criteria, received transplant, and received 1x10\^5 cells/kg
    id
    OG001
    title
    Dose 1
  3. description
    Patients who met eligibility criteria, received transplant, and received 1x10\^6 cells/kg
    id
    OG002
    title
    Dose 2
  4. description
    Patients who met eligibility criteria, received transplant, and received 1x10\^7 cells/kg
    id
    OG003
    title
    Dose 3
  5. description
    Patients who met eligibility criteria, received transplant, and were assigned the MED dose of 1x10\^7 cells/kg
    id
    OG004
    title
    Phase 2
param Type
NUMBER
population Description
Patients who met eligibility criteria and received transplant.
reporting Status
POSTED
time Frame
100 days after receiving transplant
title
The Cumulative Incidence of Transplant Related Mortality
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice